The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
IBD's proprietary RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matched up against all other stocks.
Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if Vericel stock can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Is Vericel Stock A Buy?
Vericel stock broke out on Nov. 7 and has moved more than 5% past a 50.00 entry in a first-stage double bottom, meaning it's extended and now out of a proper buy zone. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The biotech company reported 0% EPS growth in its most recent report, while sales growth came in at 27%.
Vericel stock earns the No. 45 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
